Analysis Tools
mortality/aging
|
• doxycycline-treated mice with lymphoma exhibit median survival or 5.3 months
|
neoplasm
|
• in mice treated with doxycycline from 4 to 6 weeks of age
|
|
• in the thymus and lymph nodes of mice treated with doxycycline from 4 to 6 weeks of age
|
|
• in mice treated with doxycycline from 4 to 6 weeks of age
|
integument
|
• mice treated with doxycycline for 6 weeks (either initiated at birth or 4 to 6 weeks of age) exhibit excessive hair growth compared with wild-type mice
|
|
• in mice treated with doxycycline beyond 20 weeks
• however, reactivation after 4 weeks of doxycycline prevents hair loss
|
|
• in mice treated with doxycycline beyond 20 weeks
|
craniofacial
short snout
(
J:171191
)
|
• in mice treated with doxycycline 1 to 2 days prior to birth
• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout
|
growth/size/body
short snout
(
J:171191
)
|
• in mice treated with doxycycline 1 to 2 days prior to birth
• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout
|
|
• runting in mice treated with doxycycline 1 to 2 days prior to birth
|
|
• in mice treated with doxycycline 1 to 2 days prior to birth
|
endocrine/exocrine glands
|
• in mice treated with doxycycline from 4 to 6 weeks of age
|
immune system
|
• in mice treated with doxycycline from 4 to 6 weeks of age
|
hematopoietic system
|
• in mice treated with doxycycline from 4 to 6 weeks of age
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| lymphoid leukemia | DOID:1037 | J:171191 | ||
